

Press Release – For immediate release

LABORATORY-DEVELOPED TESTS BY BIOLIDICS' LABORATORY PARTNER IN CHINA TO BE REIMBURSED UNDER CHINA'S NATIONAL BASIC MEDICAL INSURANCE PROGRAM

- **The PRC's National Healthcare Security Administration has approved the fees of the laboratory-developed tests ("LDTs") offered by Hunan Agen Lab to be reimbursed under its national basic medical insurance program**
- **Each LDT will require one Biolidics' CTChip® FR1 biochip to perform the test using Biolidics' ClearCell® FX1 System**
- **An average number of over 10,000 Chinese people are diagnosed with cancer every day, according to a report published in January 2019 by the Chinese Journal of Oncology**
- **The incidence rate of cancer in the PRC has been rising 3.9% annually over the past more than 10 years**

Singapore 1 July 2019 – Biolidics Limited ("Biolidics" or the "Company"), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that the fees related to the LDTs offered to cancer patients by its laboratory partner, Hunan Agen Medicine Laboratory Technology Co., Ltd. ("Hunan Agen Lab"), in the People's Republic of China ("PRC"), will be reimbursed by National Healthcare Security Administration of the PRC under its national basic medical insurance program.

Previously in March 2019, Biolidics announced that Hunan Agen Lab will start offering the LDTs (related to circulating tumour cells ("CTCs")) as clinical services to cancer patients. The LDTs use Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip.

Using a small amount of blood sample, the LDTs offered by Hunan Agen Lab have the potential for many applications throughout the various stages of a patient's cancer journey, such as cancer screening, cancer staging and post-cancer monitoring. The LDTs that utilises Biolidics' technology subject cancer patients to minimal invasive procedures, improve clinical outcomes, and optimise cost and efficiency.

Serving various hospitals in Hunan Province including two major hospitals, Xiangya Hospital Central South University (中南大学湘雅医院) and Hunan Cancer Hospital (湖南省肿瘤医院), Hunan Agen Lab provides multidisciplinary diagnostics, including clinical cellular and molecular genetics, clinical pathology, clinical immunology, clinical biochemistry, and advanced equipment such as Next Generation Sequencing.

Biolidics has received orders of CTChip® FR1 biochips from Hunan Agen Lab as demand for such LDT services lead to higher sales of CTChip® FR1 biochip and higher usage of ClearCell® FX1 System.

According to a report published in January 2019 by the Chinese Journal of Oncology, it was highlighted that over the past more than ten years, the incidence rate of cancer in China has experienced a rise of about 3.9% on an annual basis. Lung cancer topped the list of cancers suffered by male patients, with about 520,000 new cases discovered every year, while breast cancer, with around 304,000 new cases every year, ranked the first among other cancers suffered by female patients.

Currently, Biolidics has 3 other partnerships in the PRC, with established medical and clinical laboratories, and medical technology companies specialising in precision medicine within the oncology field, for the development and commercialisation of such LDTs in the PRC.

Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said: *“Access and affordability for cancer diagnostics are crucial in improving the clinical outcomes of cancer patients, particularly when cancer has become more prevalent in China.*

Utilising our proprietary technology and products, such LDT is a cheaper, faster and simpler alternative to an invasive tissue biopsy in the various stages of a patient's cancer journey.

With the reimbursement under China's national basic medical insurance program, we expect more cancer patients to have an opportunity to benefit from this clinical service and significantly improve the patient care experience.”

- END -

About Biolidics Limited

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.